For patients with CD4 < 100 cells/μL, studies employing the CRAG-latex test have already demonstrated a 20–40% reduction in disease-associated mortality [51,52], preventing 43% of CM deaths even at a low prevalence of 1.4% [17]. This evidence concerns the gene CD4 and cutaneous mastocytosis.